Direct Answer
Before requesting samples, an EU skincare capsules private label RFQ checklist should establish a controlled specification for the fill formula, capsule shell, mold geometry, nominal fill weight, packaging system, stability protocol, regulatory documentation, and commercial production assumptions. Without these inputs, suppliers may submit visually similar samples that are not comparable in oxidation resistance, leakage risk, dose consistency, or EU compliance readiness.
The RFQ should therefore require the ODM to identify what is fixed, what remains adjustable, and what must be revalidated after a change. It should also confirm whether the sample formula, raw-material sources, shell composition, mold, filling process, and packaging configuration can transfer to production without reformulation. For an EU launch, the buyer should align the brief with the EU Cosmetics Regulation framework and define ownership of the safety assessment, Product Information File, Responsible Person review, CPNP notification, claims support, and label verification before approving a sample.
Key Takeaways for Private Label Buyers
- Source against a specification, not an appearance. Require named shell materials, fill composition boundaries, ingredient documentation, raw-material traceability, and approved alternatives.
- Evaluate the capsule and formula as one system. Fill viscosity, solvent profile, active concentration, shell plasticization, seam integrity, and oxidation control can alter leakage and shelf performance.
- Lock packaging assumptions early. A capsule that remains stable in a blister may soften, stick, or oxidize in a repeatedly opened jar.
- Separate sample acceptance from production approval. Define the tests and documents required before pilot production, scale-up, and shipment release.
- Make change control contractual. Shell composition, mold, fill weight, antioxidants, fragrance, color, packaging, and critical suppliers should not change without documented buyer approval.
- Assess continuity as well as capability. Review backup raw materials, duplicate tooling, capacity allocation, business continuity, ESG evidence, and quality escalation procedures.
Buyer Context
Serum capsules concentrate several technical dependencies into a small format. In retinol capsules, oxygen exposure, light protection, antioxidant strategy, and fill uniformity can affect active stability. Facial oil and hair oil capsules require control of viscosity, migration, seam strength, and surface residue. Eye serum capsules introduce tighter expectations for dose size and dispensing precision. Cleansing oil capsules may contain surfactant systems that interact differently with the shell than conventional anhydrous oils.
The issue becomes more complex when a buyer requests vegan shells, custom colors, embossed shapes, or proprietary molds. A plant-derived shell is not a simple substitution for gelatin: its moisture response, sealing behavior, storage tolerance, and compatibility with the fill must be assessed as a complete system. Procurement teams comparing serum capsule products should therefore avoid treating shell claims or visual prototypes as evidence of commercial readiness.
This discipline matters most when a brand is qualifying replacement capacity after a quality incident or supply interruption, or when an existing factory lacks softgel capability. A credible cosmetic softgel capsule factory should support cross-functional review by procurement, R&D, QA, regulatory, legal, and ESG teams. Evidence should include ISO 22716 scope, audit status, deviation and CAPA controls, labor and environmental records, confidentiality safeguards, and documented production continuity. Sampling is then a controlled qualification stage rather than an isolated development exercise.
Capsule Formula, Shell, Mold, and Packaging Factors
Fill Formula and Oxidation Control
The RFQ should identify the target product type, active range, excluded ingredients, fragrance position, color requirements, and claims territory. Ask whether the fill is anhydrous, what viscosity window the filling equipment requires, and which ingredients could migrate into or weaken the shell. For encapsulated retinol skincare, request the active assay method, overage rationale, antioxidant system, light-management controls, oxygen-management process, and acceptance criteria through shelf life.
The buyer should also specify whether nitrogen blanketing, low-oxygen transfer, opaque bulk holding, or controlled processing temperatures are required. The sample certificate should report actual fill weight and relevant quality results, not merely nominal values. Confirm that the selected formula belongs to the same manufacturing route proposed for scale-up.
Shell Material and Capsule Performance
Require the exact shell composition, including gelling polymer, plasticizers, water content controls, colorants, opacifiers, and processing aids. For vegan capsule shells, request origin statements, allergen status, non-GMO status where relevant, and evidence supporting any vegan claim. Ingredient names must be reconciled with the proposed EU INCI list and safety documentation.
Shell acceptance should cover seam integrity, deformation, brittleness, tackiness, odor, color consistency, and leakage. Ask the serum capsule supplier to disclose how heat and humidity excursions affect the shell and whether conditioning is required before filling or packing. The buyer should also confirm whether the capsule is intended to twist, tear, cut, or dissolve during use, because opening performance is part of functional quality.
Mold Geometry and Fill Weight
A custom mold affects more than visual differentiation. Shape, neck dimensions, seam area, wall distribution, and cavity volume influence filling tolerance, opening force, leakage risk, tooling maintenance, and line speed. The RFQ should distinguish between an existing mold, a modified standard mold, and exclusive tooling. It should state who owns the mold, where it is stored, how it is identified, and whether duplicate tooling is available for continuity.
For private label skincare capsules, define nominal fill weight together with permissible variation and the measurement method. A heavier capsule is not automatically a better product; the dose must match the intended application, shell capacity, claims, packaging count, and consumer handling. Ask whether fill-weight adjustments require a new mold, shell change, or stability review.
Packaging Compatibility, Storage, and Shipment
Blisters generally provide stronger unit-level isolation from oxygen, moisture, and repeated handling, while jars can improve pack density but expose the remaining capsules whenever opened. Jar evaluations should consider headspace, closure seal, liner, desiccant compatibility, capsule-to-capsule sticking, surface oil, and breakage during distribution. Blister evaluations should cover cavity dimensions, lidding barrier, seal conditions, push-through behavior, and potential capsule deformation.
The stability plan should test the final formula, shell, and market packaging together under defined long-term, accelerated, heat, humidity, light, and transport conditions appropriate to the product. The buyer should request protocols, interim data, failure criteria, and responsibility for investigations. Useful planning guidance can also be reviewed in this capsule production lead-time and quality checklist and an independent EU private-label compliance checklist.
Decision Framework Table
| Factor | What to Check | Why It Matters | ODM Buyer Note |
|---|---|---|---|
| Fill formula | Composition boundaries, viscosity window, active assay, antioxidants, prohibited ingredients, and approved substitutes | Controls filling behavior, oxidation, claims support, and shell interaction | Require written approval before any ingredient or supplier substitution |
| Capsule shell | Polymer source, plasticizers, colorants, seam quality, moisture response, vegan evidence, and opening method | Determines leakage resistance, handling, storage tolerance, and label accuracy | Review complete shell composition rather than relying on a general material description |
| Fill weight | Nominal dose, permitted variation, sampling method, and batch records | Affects dose consistency, pack count, cost model, and consumer use | Confirm that sample and production acceptance criteria are identical |
| Mold and tooling | Geometry, ownership, exclusivity, maintenance, replacement lead time, and backup tooling | Influences differentiation, seam area, output, and continuity risk | Record mold identity and access rights in the quality agreement |
| Packaging | Blister barrier or jar closure, liner, headspace, desiccant, seal integrity, and distribution resistance | Packaging can determine oxidation, sticking, deformation, and leakage outcomes | Do not approve bulk capsules independently of the final pack |
| Stability and compliance | Final-pack studies, specifications, CPSR inputs, PIF documents, claims evidence, CPNP roles, and label review | Supports lawful placement on the EU market and defensible release decisions | Map every document to an owner, approval gate, and delivery date |
| MOQ and sample scope | Sample quantity, pilot MOQ, scale-up assumptions, testing inclusions, and resampling triggers | Prevents an attractive prototype from masking an unqualified production route | Use the same approved formula, shell, mold, and process for pilot and commercial production |
| Shipment conditions | Temperature exposure, humidity protection, case configuration, pallet pattern, and data logging | Protects capsules after factory release and supports root-cause analysis | Assign responsibility for excursion review before the first commercial shipment |
A disciplined comparison of cosmetic softgel products should score evidence quality, change-control maturity, and continuity risk alongside formula performance. For oxidation-sensitive formats such as retinol softgel capsules, procurement approval should remain conditional until the final packaging configuration and stability plan have passed cross-functional review.
ODM Manufacturing Considerations
Sample approval should be treated as a controlled manufacturing gate rather than a visual preference check. The buyer and supplier should sign a sample confirmation sheet covering capsule appearance, measured viscosity range, capsule-to-capsule mass data, odor, break force, application feel, and the approved primary pack. Retain sealed reference samples from the accepted batch and record the formula version, shell grade, mold code, packaging lot, and production date. This becomes especially important when qualifying a replacement source after a quality incident or sudden capacity interruption at the incumbent manufacturer.
For fill formula customization, clarify whether development starts from an existing base, a buyer-supplied formula, or a new brief. Ask which ingredients have concentration, solubility, color, fragrance, or shell-contact limitations. Retinol capsules, facial oil capsules, eye serum capsules, cleansing oil capsules, and hair oil capsules can behave differently even when their initial bench appearance is similar. The RFQ should therefore request ingredient documentation, a manufacturing method summary, measurable release specifications, and a change-control process. Buyers can review related formats through the supplier’s capsule technology and retinol capsule resources before finalizing the brief.
Shell selection should identify animal-derived or vegan status, color system, opacity, plasticizer approach, and known interaction constraints. Mold selection should define the available shape, dimensions, closure style, unit dose, branding feasibility, and whether future production can use the same geometry. Ask for actual samples from the intended mold rather than approving a rendering.
Packaging should be tested as a complete configuration. Confirm how the capsule behaves against the selected blister cavity, foil, jar, liner, closure, and any internal component. The stability plan should list checkpoints, test conditions, failure criteria, and responsibility for investigating changes in odor, color, tack, break force, or fill appearance. For procurement planning, separate minimum order requirements for development batches, stock-shape capsules, custom colors, printed components, and finished packed goods. Also ask when each minimum becomes financially committed.
Labeling files should include the ingredient list, formula and finished-product specifications, batch certificate format, safety information where applicable, fragrance allergen data, artwork dimensions, traceability codes, and evidence supporting cosmetic claims. Shipment instructions should state carton configuration, pallet limits, seasonal routing precautions, acceptable dispatch window, and data logger requirements where justified. Production slot planning and documentation timing are discussed further in this capsule production lead-time guide.
Common Problems or Failure Cases
Shell brittleness: Capsules may crack during packing or consumer handling when shell moisture balance, storage environment, or formula-shell interaction moves outside the qualified range. Buyers should request break-force results at multiple study checkpoints, not only at release.
Sticking and deformation: Capsules can become tacky, flatten, or adhere to neighboring units. This may arise from unsuitable storage, residual surface material, excessive pressure inside a jar, or migration from the fill. Review samples in the intended count and pack orientation.
Fill separation: A clear oil may develop sediment, haze, color bands, or uneven active distribution. The investigation should distinguish normal temperature-related appearance from irreversible separation. Request photographs, assay or homogeneity data where relevant, and a defined acceptance standard.
Leakage: Small seal defects can contaminate adjacent capsules and packaging before they are obvious during incoming inspection. An RFQ should ask how the supplier detects weak seals, records defect rates, and handles affected lots.
Fragrance sensitivity: Fragrance components can alter odor, shell texture, or consumer tolerance over time. The approved fragrance must be evaluated in the actual capsule system rather than inferred from a conventional bottled serum.
Packaging deformation: A capsule may remain acceptable while a blister cavity, liner, or jar component warps, discolors, or absorbs oil. This is why packaging release should rely on assembled-pack evidence rather than separate component certificates alone.
Supplier Checklist
- Confirm the legal manufacturer, production site, subcontractors, and scope performed at each location.
- Request the complete shell composition, origin status, colorants, and supporting vegan or Halal evidence when claimed.
- Obtain the fill viscosity range, ingredient documentation, fill-weight report, and finished-product release specification.
- Review mold code, dimensions, available unit sizes, maintenance responsibility, and continuity arrangements.
- Approve an identified reference sample with formula, shell, mold, and packaging version controls.
- Check protocols and results for shell integrity, leakage, appearance, odor, fill uniformity, and pack interaction.
- Separate minimum quantities and lead times by development, capsule production, decoration, and final packing stage.
- Verify label inputs, claim substantiation, batch records, certificate formats, complaint records, and change notification periods.
- Define carton, pallet, warehouse, dispatch, and seasonal shipping requirements in the purchase specification.
- Audit information security, environmental records, insurance coverage, and business-continuity controls using objective evidence.
FAQ
Can a capsule supplier guarantee that our core formula will never be disclosed?
No supplier can credibly promise absolute security. Ask for role-based system access, formula-master audit logs, segregated development records, physical access restrictions, confidentiality terms, employee offboarding controls, backup governance, and cyber-incident procedures. The contract should define ownership of buyer-provided formulas, permitted access, subcontractor restrictions, and remedies for unauthorized disclosure.
How can a buyer verify environmental and carbon reporting?
Request site-specific utility data, waste and wastewater records, permit status, reporting boundaries, calculation methods, reduction targets, and independent assurance reports. Confirm that evidence covers the factory producing the capsules rather than a parent company’s consolidated figures. This is particularly important when headquarters requires measurable progress toward a global supplier carbon target.
What insurance evidence is relevant to a major capsule quality complaint?
Review current product liability and recall policies, territorial scope, exclusions, per-event and aggregate limits, deductibles, and the insured legal entity. Confirm whether coverage applies to the intended sales countries and whether the supplier can fund investigation, withdrawal, destruction, and replacement costs before an insurer resolves the claim.
Should we approve the laboratory sample or the first production batch?
Approve both at different stages. The laboratory sample confirms the development direction, while a production-representative batch confirms manufacturability, shell behavior, unit consistency, packaging fit, and release documentation. The agreement should state which approval authorizes component purchasing and commercial scheduling.
What documents are needed for a vegan capsule claim?
Ask for the full shell composition, supplier declarations, processing-aid information, cross-contamination controls, and the finished-product claim basis. A marketing statement on a website is not sufficient evidence. If Halal positioning is also planned, confirm certification scope against the JAKIM Halal certification framework.
What should happen when capsules become brittle or sticky during review?
Quarantine the affected samples and record storage history, pack type, lot numbers, photographs, and defect frequency. The supplier should compare retained controls, test shell properties, inspect the fill and packaging contact surfaces, and issue a documented root-cause and corrective-action report before further approval.